By Laura Shin
Posting in Science
The experiment will be conducted on members of the world's largest family afflicted with a genetic marker for the disease.
The U.S. announced on Tuesday an unprecedented drug trial aimed at preventing Alzheimer's, a disease that gradually causes dementia.
The experiment is unusual for two reasons: The drug will be administered to subjects who are ostensibly healthy. A majority of them will, however, be genetically predisposed to develop the disease.
Also, it will be one of the few experiments to be conducted on people with a genetic predisposition to any disease.
The subjects will mostly be members of the world's largest family afflicted with Alzheimer's. In this Colombian family, who reside in and around Medellin, those who have a specific gene mutation normally show first Alzheimer's symptoms at 45 and full dementia at 51. Eventually, not only do their memories fade, but also their ability to move, eat and communicate.
While the whole clan number 5,000, the $100 million, five-year trial, which begins in 2013, will be conducted on 300 subjects, some as young as 30. A few Americans unrelated to the family will be tested as well.
The drug, Crenezumab, targets one of the brain substances thought by many to be a cause of Alzheimer's: amyloid plaques. More specifically, ABC reports that it attacks ABeta, a component of those plaques, that accumulates in the brains of people with this genetic mutation.
The trial will look to see whether the drug helps delay or even prevent memory problems in the subjects with the genetic marker, and find out at what age the drug needs to be administered to prevent dementia.
If keeping the brain clear of clumps of amyloid plaques does appear to stave off memory decline, future trials could just look at amyloid levels to determine the success of a treatment rather than waiting to see whether patients' memories deterioriate.
Crenezumab was chosen because it does not yet appear to have negative side effects, whereas other amyloid-attacking drugs do. Researchers are currently conducting two clinical trials of the drug on people who have mild or moderate symptoms of dementia to see if it reduces their amyloid plaque levels or reduces their cognitive decline.
The experiment will be composed of three groups of 100 people: 100 family members with the mutation who will receive the drug every two weeks; 100 with the mutation who receive a placebo; and 100 non-carriers who will also receive a placebo. (Because many people do not want to know whether they carry the gene, the presence of non-carriers means that participants won't know if they have it.)
Researchers will run a range of tests on the subjects. First, they will measure memory and cognition with a series of tests that detect otherwise unnoticed changes in recall and thinking. Some of the skills tested include recalling words, naming objects, nonverbal reasoning, remembering time and place, and drawing by copying complex figures.
They will also test the subjects' emotional states. Dr. Pierre N. Tariot, director of the Banner Institute and a leader of the study, told The New York Times, “irritability, sadness, crying, anxiety, impulsivity — these are cardinal features of the disease as it emerges.”
The researchers will also note physiological changes in the size of the brain, and in levels of amyloid and tau, a protein found in dying brain cells. Improvements in any of these areas would indicate to scientists that they could treat any of these early physiological changes in the same way that treating high blood pressure can help prevent heart disease.
Though the experiment is scheduled to last five years, tests could show whether the drug is effective as early as two years in.
Related on SmartPlanet:
- Stem cell breakthrough could bring cure for genetic diseases
- Exercise shown to stave off Alzheimer's in high-risk subjects
- $300 million to find out how the brain perceives
- Coming soon: $1,000 to map your genes
- Video: First 'chimera' monkeys created from multiple embryos
- Chinese medical school teaches genetics using Harry Potter
- Top 10 most interesting genetic findings of 2011
May 17, 2012
Welcome To Our Winter Coats Moncler Outlet Online Store,Very popular Moncler Jackets been is recognized as the mountain, but the jacket to make their way to the Italian style and Tokyo show Moncler Coats. In this era, personal clothing, even more than a great visual appeal Cheap Moncler Coats, has tried to keep the function of the Moncler Vests by a fashionable goods, although provide, but as wise, because it really should manage its people. Throughout 1980 S Moncler women become vogue and people began to coat the hillside, from their coat to go out, this will help enhance the brand image, the famous and profits. The next big changes occurred in 2003, when it is by the Cheap Moncler Vests Italian entrepreneurs and fashion fans don't LuFei ray, bought tags. Riffini on a product's shape, make the leading fashion brand Cheap Moncler Jackets a larger one of the key, and in 2006, they introduced a has been shown to be a great signing. Now Moncler fashion brand, has become the first women's Olympic Games they French fashion series standard equipment. The team in the real religion jeans Moncler era, because it is a very comfortable leading quilting fugu jacket manufacturers recognition, but they are more than that, Tom brown and other loan designers,
Title:Moncler Jackets On www.Echeapjackets4moncler.com Label:Moncler Jackets,Moncler Coats,Cheap Moncler Jackets Content: The Moncler Jackets company started its production in 1954 when it provided the equipment for the Cheap Moncler Jackets Italian expedition led by Ardito Desio that accomplished the successful first Moncler Coats ascent to the summit of K2 on 13 July 1954. Cheap Moncler Coats provided the equipment for the French expedition led by Jean Franco that conquered Makalu on 15 (by Lionel Terray and Jean Couzy), 16 (by Franco, G. Magnone, and Sardar Gyaltsen Norbu), and 17 (by Bouvier, S. Coupe, Leroux, and A. Vialatte) May 1955. In 1964, the company organized the expedition led by Ramillon's friend and world-renowned climber Lionel Terray, which led to the successful first ascent of 12,240 foot (3,730 m) Mount Huntington, in the Alaska Range, by the northwest ridge. In fact, Terray was a key figure in the history of the company that started develop the first line specialized for climbing at high altitude "Moncler pour Lionel Terray". In 1968, Moncler was the official supplier of the French national team during the 1968 Winter Olympics in Grenoble, France. Also, during this period, Moncler adopted the cockerel as its symbol by www.Echeapjackets4moncler.com .
For the sake of humanity and to prevent the huge losses that otherwise America will suffer, I hope that the trials are successful. Wouldn't it be something if the government was to step in and issue this (free) to people genetically predisposed for the condition? A healthier America is a happier and more productive America.